Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

医学 彭布罗利珠单抗 多西紫杉醇 西妥昔单抗 内科学 打开标签 肿瘤科 头颈部 甲氨蝶呤 头颈部鳞状细胞癌 临床研究阶段 外科 头颈部癌 癌症 随机对照试验 化疗 放射治疗 结直肠癌 免疫疗法
作者
Ezra E.W. Cohen,Denis Soulières,Christophe Le Tourneau,José Dinis,Lisa Francesca Licitra,Myung‐Ju Ahn,Ainara Soria,Jean‐Pascal Machiels,Nicolas Mach,Ranee Mehra,Barbara Ann Burtness,Pingye Zhang,Jonathan D. Cheng,Ramona F. Swaby,Kevin Joseph Harrington,Mirelis Acosta-Rivera,Douglas R. Adkins,Morteza Aghmesheh,Myung‐Ju Ahn,Mario Airoldi
出处
期刊:The Lancet [Elsevier BV]
卷期号:393 (10167): 156-167 被引量:1718
标识
DOI:10.1016/s0140-6736(18)31999-8
摘要

Summary

Background

There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour activity and manageable toxicity in early-phase trials. We aimed to compare the efficacy and safety of pembrolizumab versus standard-of-care therapy for the treatment of head-and-neck squamous cell carcinoma.

Methods

We did a randomised, open-label, phase 3 study at 97 medical centres in 20 countries. Patients with head-and-neck squamous cell carcinoma that progressed during or after platinum-containing treatment for recurrent or metastatic disease (or both), or whose disease recurred or progressed within 3–6 months of previous multimodal therapy containing platinum for locally advanced disease, were randomly assigned (1:1) in blocks of four per stratum with an interactive voice-response and integrated web-response system to receive pembrolizumab 200 mg every 3 weeks intravenously or investigator's choice of standard doses of methotrexate, docetaxel, or cetuximab intravenously (standard-of-care group). The primary endpoint was overall survival in the intention-to-treat population. Safety was analysed in the as-treated population. This trial is registered with ClinicalTrials.gov, number NCT02252042, and is no longer enrolling patients.

Findings

Between Dec 24, 2014, and May 13, 2016, 247 patients were randomly allocated to pembrolizumab and 248 were randomly allocated to standard of care. As of May 15, 2017, 181 (73%) of 247 patients in the pembrolizumab group and 207 (83%) of 248 patients in the standard-of-care group had died. Median overall survival in the intention-to-treat population was 8·4 months (95% CI 6·4–9·4) with pembrolizumab and 6·9 months (5·9–8·0) with standard of care (hazard ratio 0·80, 0·65–0·98; nominal p=0·0161). Fewer patients treated with pembrolizumab than with standard of care had grade 3 or worse treatment-related adverse events (33 [13%] of 246 vs 85 [36%] of 234). The most common treatment-related adverse event was hypothyroidism with pembrolizumab (in 33 [13%] patients) and fatigue with standard of care (in 43 [18%]). Treatment-related death occurred in four patients treated with pembrolizumab (unspecified cause, large intestine perforation, malignant neoplasm progression, and Stevens-Johnson syndrome) and two patients treated with standard of care (malignant neoplasm progression and pneumonia).

Interpretation

The clinically meaningful prolongation of overall survival and favourable safety profile of pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma support the further evaluation of pembrolizumab as a monotherapy and as part of combination therapy in earlier stages of disease.

Funding

Merck Sharp & Dohme, a subsidiary of Merck & Co.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
缥缈芒果完成签到,获得积分10
1秒前
ZZD完成签到 ,获得积分10
1秒前
开心的老虎完成签到,获得积分10
1秒前
zjw发布了新的文献求助30
1秒前
灰灰完成签到,获得积分10
2秒前
kokok发布了新的文献求助20
2秒前
2秒前
敏感寒云完成签到,获得积分10
2秒前
JG发布了新的文献求助10
2秒前
ing完成签到 ,获得积分10
2秒前
青柳安发布了新的文献求助10
3秒前
ERIC完成签到,获得积分10
3秒前
Jenny完成签到,获得积分10
3秒前
溜溜完成签到,获得积分10
3秒前
wwww发布了新的文献求助10
3秒前
3秒前
3秒前
3秒前
自觉鸽子完成签到,获得积分10
4秒前
elsa完成签到,获得积分10
4秒前
柏四月完成签到,获得积分10
4秒前
xy完成签到,获得积分10
4秒前
Akim的应助被科研废材采纳,获得30
4秒前
夏飞飞完成签到,获得积分10
4秒前
Yang完成签到,获得积分0
4秒前
斯文败类的应助被明芷蝶采纳,获得10
5秒前
脑洞疼的应助被yang采纳,获得10
5秒前
宜醉宜游宜睡完成签到,获得积分0
5秒前
xxxx发布了新的文献求助10
5秒前
康康发布了新的文献求助10
5秒前
zwy完成签到,获得积分20
6秒前
6秒前
王醉山完成签到,获得积分10
6秒前
6秒前
小恒202完成签到,获得积分10
7秒前
杏仁鹿完成签到 ,获得积分10
7秒前
7秒前
Luo完成签到,获得积分10
7秒前
7秒前
xx完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159633
求助须知:如何正确求助?哪些是违规求助? 9555145
关于积分的说明 21725138
捐赠科研通 7749593
什么是DOI,文献DOI怎么找? 3427281
关于科研通互助平台的介绍 2552345
邀请新用户注册赠送积分活动 2471619